Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
University of Hawaii
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
59High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00986986CT.gov Study of Niacin on Endothelial Function in HIV-infected Subjects With Low High Density Lipoprotein Cholesterol Levels | — | Completed | — | — | — |
NCT00659321CT.gov Efficacy of Nicotine Acid on Dyslipidaemia in Patients With Metabolic Syndrome | — | Completed | — | — | — |
NCT01216956CT.gov Metabolic Effects of an 8 Week Niaspan Treatment in Patients With Abdominal Obesity and Mixed Dyslipidemia | — | Completed | — | — | — |
NCT00079638CT.gov Comparative Efficacy Evaluation of Lipids When Treated With Niaspan & Statin or Other Lipid-Modifying Therapies-COMPELL | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Inherited Lipid Metabolism Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Niacin (this asset) | University of Hawaii | Approved | BB · 68 |
| Atorvastatin | Johns Hopkins University | P4 | A |
| Rosuvastatin | Korea University Anam Hospital | P4 | A |
| Metformin | RenJi Hospital | P4 | BBB |
| Simvastatin | Eli Lilly and Company | P4 | BBB |
| Ezetimibe | Samsung Medical Center | P4 | BBB |
| Fenofibrate | Lewai Sharki Abdulaziz, MSc PhD | P4 | BBB |
| Umbellatine | China National Center for Cardiovascular Diseases | P4 | BBB |
| Fluvastatin | Novartis | P4 | BB |
+42 more in the Inherited Lipid Metabolism Disorder cohort
Other indications for Niacin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Abdominal Obesity-Metabolic Syndrome | — | P4 | BB · 68 |
| Coronary Artery Disorder | — | P4 | BB · 68 |
| Stroke Disorder | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Niacin in Inherited Lipid Metabolism Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 13, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/niacin-inherited-lipid-metabolism-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →